Russell Investments Group’s Evogene EVGN Stock Holding History

Russell Investments Group’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$1	–	4261
2025 Q4	$1	Buy	+1	New	+$1	﹤0.01%	4174

Other funds holding EVGN

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

DSC

Daytona Street Capital Saint Louis, Missouri $130M AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Russell Investments Group's EVGN Position: Q1 2026 in Review

Russell Investments Group sold out of Evogene (EVGN) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.

Russell Investments Group first reported a position in EVGN in Q4 2025 and held it in 1 quarter. The position peaked at $1 in Q4 2025. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

Russell Investments Group reported no remaining Evogene position as of Q1 2026 after selling out during the quarter.
Russell Investments Group sold 1 Evogene share in Q1 2026, an estimated $1.
Russell Investments Group first reported a position in Evogene in Q4 2025 and held it in 1 quarter.
Russell Investments Group's Evogene position peaked at $1 in Q4 2025.
15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.